PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
March 14, 2026BMC Medicine0 citationsOpen Access

The role of male foetal sex on maternal and neonatal outcomes in pregnancies complicated by gestational diabetes—secondary analysis of a randomised placebo controlled clinical trial of metformin in gestational diabetes (EMERGE)

View Full Paper
CNChristine NewmanAAA. Alvarez-IglesiasKEKeelan Eyers

Key Points

  • This analysis aims to assess how male foetal sex influences maternal and neonatal outcomes in gestational diabetes and the effects of metformin.
  • Conducted a secondary analysis of the EMERGE randomised controlled trial.
  • Analyzed outcomes based on foetal sex and metformin exposure.
  • Evaluated insulin usage, fasting glucose levels at 32 and 38 weeks, and foetal size.
  • Higher plasma glucose levels at 60 minutes in women carrying male foetuses (9.69 vs. 9.37 mmol/L, p = 0.039).
  • Male pregnancies showed lower fasting glucose levels with metformin at 32 weeks (4.88 vs. 5.01 mmol/L, p = 0.014) and 38 weeks (4.49 vs. 4.69 mmol/L, p = 0.002).
  • Reduced insulin usage in male pregnancies exposed to metformin (38% vs. 53%, p = 0.014).
  • Female metformin-exposed offspring had higher rates of low birth weight (<2500 g) compared to placebo (8.3% vs. 1.9%, p = 0.032), an observation not seen in males.

Abstract

Male foetal sex is recognised as an independent risk factor for adverse pregnancy outcomes including preterm birth, neonatal care unit admission and lower Apgar scores. Male foetuses appear to increase the risk of maternal gestational diabetes in the mother due to impacts on beta cell function, and in pregnancies impacted by gestational diabetes, male offspring have higher rates of hypoglycaemia, respiratory distress and macrosomia. Metformin exposure in animal models has also demonstrated sex-specific effects with different patterns in adiposity and lipid levels observed between male and female offspring exposed to metformin in utero. The aim of this analysis is to determine whether foetal sex modifies maternal and neonatal outcomes in gestational diabetes, and evaluate the sex-specific response to metformin on insulin usage, fasting glucose at 32 and 38 weeks and foetal size. We conducted a secondary analysis of the Early Metformin in Gestational Diabetes (EMERGE) randomised controlled trial and analysed neonatal outcomes according to sex and metformin exposure. At randomisation, women carrying a male foetus had a higher plasma glucose at 60 min on oral glucose tolerance testing (9.69 vs. 9.37 mmol/L, p = 0.039). In exploratory analyses, metformin exposure in male pregnancies was associated with lower fasting glucose at 32 (4.88 vs. 5.01 mmol/L, p = 0.014) and 38 weeks (4.49 vs. 4.69 mmol/L, p = 0.002) and reduced insulin use (38% vs. 53%, p = 0.014), with smaller effects in female pregnancies. Metformin-exposed females had higher rates of birth weight 4000 g compared to female offspring regardless of metformin exposure. However, the sex-by-treatment interaction was not significant, so these findings should be regarded as hypothesis-generating. Glucometer data suggested a greater mean glucose reduction in males than females (0.29 mmol/L (95% CI 0.29–0.30) versus 0.21 mmol/L (95% CI 0.20–0.21)). Further follow-up is required to determine whether foetal sex influences long-term effects of metformin in pregnancy.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Newman et al. (2026) studied this question.

synapsesocial.com/papers/69b4fc6ab39f7826a300d3c8https://doi.org/10.1186/s12916-026-04778-z
Ask AI
Helpful
Bookmark
Share
View Full Paper